Most Read Articles
23 Sep 2018
Supplementation with n−3 or omega-3 fatty acids does not help prevent serious vascular events in diabetic patients without evidence of cardiovascular disease at baseline, according to a study.
6 days ago
At a webinar hosted by Pfizer, leading Malaysian family medicine specialists Professor Chia Yook Chin andProfessor Sherina Mohd Sidik discussed a host of issues commonly encountered in primary care, includingpreventing cardiovascular (CV) disease, pain control in osteoarthritis (OA) and depression management.
Rachel Soon, 31 Jan 2019

More home blood pressure (BP) and office BP measurements should be encouraged to identify otherwise hidden cases of hypertension, said an expert.

Tristan Manalac, 04 Aug 2018
Omega-3 fatty acid (FA) supplements do not yield significant cardiovascular benefits, according to a recent meta-analysis, which shows no reduction in fatal or nonfatal coronary heart disease (CHD) or major vascular events following supplementation.

Pharmacoinvasive therapy, PPCI confer comparable survival benefits to transfer STEMI patients

11 Sep 2018

Pharmacoinvasive therapy (PIT) and primary percutaneous coronary intervention (PPCI) are comparable in terms of all-cause mortality in transfer patients with ST-elevation myocardial infarction (STEMI), a recent meta-analysis has shown.

Seventeen studies were eligible for inclusion in the meta-analysis, of which six were randomized controlled trials (RCTs) and 11 were cohort studies. Together, the studies corresponded to 13.037 patients who received either PPCI (n=7,398) or PIT (n=5,693). No evidence of small study effects or publication bias was reported.

Pooled analysis of the six RCTs showed PIT and PPCI were statistically comparable in terms of all-cause, short-term (odds ratio [OR], 0.99; 95 percent CI, 0.73–1.34; p=0.93) and long-term (OR, 0.83; 0.59–1.17; p=0.287) mortality. On the other hand, PPCI significantly increased the risk of all-cause, short-term mortality, according to the pooled analysis of observational studies (OR, 1.39; 1.04–1.87; p=0.028).

However, combining both RCTs and observational studies demonstrated that both approaches resulted in similar likelihood of all-cause short-term (OR, 1.20; 0.97–1.49; p=0.099) and long-term (OR, 1.17; 0.84–1.62; p=0.361) mortality.

The same was true for total stroke (OR, 0.76; 0.51–1.49; p=0.193), haemorrhagic stroke (OR, 0.56; 0.20–1.62; p=0.288), ischaemic stroke (OR, 0.65; 0.28–1.49; p=0.310) and major bleeding (OR, 0.73; 0.48–1.11; p=0.138).

In contrast, PPCI significantly increased the risk of cardiogenic shock (OR, 1.48; 1.13–1.94; p=0.005) and decreased the chances of reinfarction (OR, 0.69; 0.49–0.97; p=0.033) relative to PIT.

The databases of Embase, Scopus, PubMed and the Cochrane Library were accessed for the present meta-analysis. Studies on facilitated PCI and with ischaemia-guided reperfusion were excluded. The Newcastle-Ottawa scale was used to evaluate study quality.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
23 Sep 2018
Supplementation with n−3 or omega-3 fatty acids does not help prevent serious vascular events in diabetic patients without evidence of cardiovascular disease at baseline, according to a study.
6 days ago
At a webinar hosted by Pfizer, leading Malaysian family medicine specialists Professor Chia Yook Chin andProfessor Sherina Mohd Sidik discussed a host of issues commonly encountered in primary care, includingpreventing cardiovascular (CV) disease, pain control in osteoarthritis (OA) and depression management.
Rachel Soon, 31 Jan 2019

More home blood pressure (BP) and office BP measurements should be encouraged to identify otherwise hidden cases of hypertension, said an expert.

Tristan Manalac, 04 Aug 2018
Omega-3 fatty acid (FA) supplements do not yield significant cardiovascular benefits, according to a recent meta-analysis, which shows no reduction in fatal or nonfatal coronary heart disease (CHD) or major vascular events following supplementation.